Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Jane Wolstenholme

Dr Jane Wolstenholme

Jane Wolstenholme

BA(Hons), MSc, PhD

Associate Professor of Health Economics

I have over 25 years of experience in conducting economic evaluations for health policy makers and exploring methodological issues relating to the design and analysis of economic evaluations. I have been a health economist at HERC since 1998, prior to that a research associate at the University of Nottingham. 

My research programme has focused on the health economics of cancer, with current research on trial-based evaluations and methodology related to prostate, breast and head and neck cancer. Previous published research relates to the economic evaluation of interventions for prostate, breast, cervical and lung cancer.

My main research interests include designing and conducting economic evaluations alongside trials and cost-effectiveness models. I am principal investigator and co-applicant on a wide variety of funded research projects, across a number of disease areas and health-care technologies, including cancer, chronic kidney disease, obesity, mental health, point of care and in-vitro diagnostics.

I am a health economics adviser for the NIHR RDS South Central and the lead health economist for the NIHR Community Healthcare Medtech and In Vitro Diagnostics Co-operative, Oxford University.  

I supervise MSc and DPhil students.  Examples of current doctoral research:

  • Exploring the cost-effectiveness of chronic disease prevention strategies using local area chronic disease scenario modelling.
  • Developing a modelling framework for providing individualised estimates of comparative outcomes and cost-effectiveness for competing radiotherapy technologies in cancer patients. 

I have published widely and I’m co-author of a major OUP text book ‘Applied Methods of Cost-effectiveness Analysis in Health Care’.